MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

37.84 0.83

Buy Sell

Overview

Share price change

24h

Current

Min

37.08

Max

37.85

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	11.593 87.826
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+18.64% upside

Market Stats
By TradingEconomics
Market Cap	429M 2.1B
Previous open	37.01
Previous close	37.84

News Sentiment

By Acuity

34%

66%

106 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sty 2026, 23:11 UTC

Earnings

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 sty 2026, 22:55 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 sty 2026, 21:39 UTC

Major Market Movers

Raytheon Down Following Trump Post Criticizing Company

7 sty 2026, 20:13 UTC

Major Market Movers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 sty 2026, 20:03 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 sty 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 sty 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 sty 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 sty 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 sty 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 sty 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 sty 2026, 22:46 UTC

Earnings

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 sty 2026, 22:45 UTC

Earnings

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 sty 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 sty 2026, 22:42 UTC

Earnings

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 sty 2026, 22:40 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 sty 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 sty 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 sty 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 sty 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 sty 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 sty 2026, 21:18 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 sty 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 sty 2026, 20:29 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 sty 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 sty 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 sty 2026, 19:48 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

18.64% upside

12 Months Forecast

Average 43.6 USD 18.64%

High 55 USD

Low 32 USD

Based on 6 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

106 / 372 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.